Curebio Therapeutics is engaged in the discovery and development of potential first-in-class medicines based  on newly discovered pathway effected by ARSs (Aminoacyl tRNA Synthetases)

·Translating novel biology ARS into first-in-class therapies

·MOA of our pipelines was published at eminent academic  journals

CEO

Hyo Sung Kwon, Ph.D

• ©NDFOS / Bio Business Division

• ©NEXEL Business / Development Team Manager

• ©Cellivery Therapeutics / Business Development Team Manager

• Korea University Biomedical Engineering Ph.D.

Director

Hae Sung Lee

•©CKD Research Institute 

•©Hanwha Dream Pharm. 

•©Bukwang Pharm.

•National Institute of Food and Drug Safety Evaluation

•Sungkyunkwan University Bio Engineering M.S.

Scientific Advisory Board

Prof. Roger Kornberg

•2006 Novel Prize Winner in Chemistry

•Stanford Medicine, Department of Structural Biology / Professor

•Stanford, Chemical Physics, Ph.D.

•Harvard, Chemistry, BSc

Scientific Advisory Board

Prof. Se Chan Kang

•Kyung Hee University / College of Life Sciences Prof. / Director of Institute of Biotechnology

•Head of Kyung Hee University Affiliated Biomedical Research Center

•University of Munich / Visitiing Prof.

•The Plant Resources Society of Korea / Vice President

•The Korean Society of Medicinal Crop / Executive Director

•Sungkyunkwan University Pharmacy Ph.D.